Evolocumab “must become cheaper” to be cost effective in enhancing benefits of statinsBMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4042 (Published 30 August 2017) Cite this as: BMJ 2017;358:j4042
- Nigel Hawkes
Evolocumab, a cholesterol lowering drug that may enhance the benefits of statins, will need to be sold at a much lower price to be cost effective, two studies have found, but they disagree on how deep this price cut would need to be.
A team led by Dhruv Kazi, of Zuckerberg San Francisco Hospital in California, USA, found that the listed price for evolocumab (Repatha) would need to be reduced by more than two thirds to meet a cost effectiveness threshold of $100 000 (£77 300; €83 200) per quality adjusted life year (QALY). Evolocumab, made by Amgen, has a US list price of more than $14 000 a year—but a price no greater than $4215 a year would be required …